"Patients who experience hyperkalemia while on RAAS inhibitor therapy may benefit from intensification of other evidence-based preventative measures against adverse cardiorenal outcomes, such as lipid ...

Hyperkalemia Risk May Be Higher With MRA-RAAS Inhibitor Combo Three studies published in the New England Journal of Medicine on May found no evidence that the use of ACE inhibitors or ...

Please provide your email address to receive an email when new articles are posted on . Fewer patients with hyperkalemia were prescribed renin-angiotensin-aldosterone system inhibitors for HF.

A woman reaching for a prescription bottle in a medicine cabinet Discontinuation of RAAS inhibitors is often the first approach to manage hyperkalemia. Discontinuation of renin–angiotensin-aldosterone ...

Treatments that target the renin-angiotensin-aldosterone system (RAAS) don’t improve outcomes in adult patients hospitalized with acute COVID-19. Three separate trials of different RAAS-related ...

At one time, dual RAAS blockade was expected to provide more-complete inhibition of RAAS among patients with DKD. Results of large clinical trials dashed these hopes, finding increased risk of AKI and ...

We may have reached the point where we have achieved all of the morbidity/mortality benefits that are possible by targeting the renin-angiotensin-aldosterone system (RAAS) in symptomatic heart failure ...

What if there were a straightforward and relatively inexpensive way to lower the incidence of heart failure (HF), renal disease, stroke, and cognitive impairment? Cardiologist Bertram Pitt, MD, said ...

The risk for hyperkalemia was highest with use of steroidal MRAs in combination with other RAASi. In patients with diabetic kidney disease, use of 2 classes of renin-angiotensin-aldosterone system ...